Methicillin-Resistant Staphylococcus aureus (MRSA) – Current and Future Players

GlobalData has released its pharma report, “Methicillin-Resistant Staphylococcus aureus (MRSA) – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MRSA Market. The report identifies and analyses the key companies shaping and driving the global MRSA market. The report provides insight into the competitive MRSA landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Investigation of current and future market competition for MRSA

Competitor assessment

Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

Strategic assessment of MRSA sector through market impact analysis, future market scenario and company analysis

Reasons to buy

Gain a high level view of the trends shaping and driving MRSA market

Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

Create an effective counter-strategy to gain a competitive advantage against those currently in the market

What’s the next big thing in the global MRSA market landscape? Identify, understand and capitalize

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Market Outlook

3.1Global Markets

3.1.1Forecast

3.1.2Drivers and Barriers – Global Issues

4Current and Future Players

4.1Overview

4.2Trends in Corporate Strategy

4.3Company Profiles – Current Players

4.3.1Pfizer

4.3.2Merck

4.3.3Allergan

4.3.4The Medicines Company

4.3.5Theravance Biopharma

4.3.6Basilea Pharmaceutica

4.3.7Sanofi

4.4Additional Companies with Promising Pipeline Products

4.4.1Melinta Therapeutics

4.4.2Cempra Pharmaceuticals

4.4.3Paratek Pharmaceuticals

4.4.4Kyorin Pharmaceutical

4.4.5Nabriva Therapeutics

4.4.6Debiopharm International

4.4.7Cellceutix Corporation

5Appendix

5.1Bibliography

5.2Abbreviations

5.3Methodology

5.4Forecasting Methodology

5.4.1Hospitalized MRSA Patients

5.4.2Percentage of Drug-Treated MRSA Patients

5.4.3Drugs Included in Each Therapeutic Class

5.4.4Launch, Label Expansion, and Patent Expiry Dates

5.4.5General Pricing Assumptions

5.4.6Individual Drug Assumptions

5.4.7Generic Erosion

5.4.8Pricing of Pipeline Agents

5.5Primary Research – KOLs Interviewed for This Report

5.6Primary Research – Prescriber Survey

5.7About the Authors

5.7.1Author and Therapy Area Director

5.7.2Author

5.7.3Epidemiologist

5.7.4Global Director of Therapy Analysis and Epidemiology

5.7.5Global Head of Healthcare

5.8About GlobalData

5.9Disclaimer

List of Tables

Table 1: Global Sales Forecasts ($m) for MRSA Therapeutics, 2014–2024

Table 2: MRSA Therapeutics Market – Global Drivers and Barriers, 2014–2024

Table 3: Key Companies in the MRSA Marketplace in the 7MM, 2015

Table 4: Pfizer’s MRSA Portfolio Assessment, 2015

Table 5: Merck’s MRSA Portfolio Assessment, 2015

Table 6: Allergan’s MRSA Portfolio Assessment, 2015

Table 7: The Medicines Company’s MRSA Portfolio Assessment, 2015

Table 8: Theravance Biopharma’s MRSA Portfolio Assessment, 2015

Table 9: Basilea Pharmaceutica’s MRSA Portfolio Assessment, 2015

Table 10: Sanofi’s MRSA Portfolio Assessment, 2015

Table 11: Companies with Promising Pipeline Candidates for MRSA in the 7MM, 2015

Table 12: Key Historical and Projected Launch Dates for MRSA Across the 7MM

Table 13: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM

Table 14: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM

Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales for MRSA Therapeutics by Country, 2014 and 2024

Figure 2: Global Sales for MRSA Therapeutics by Region, 2014–2024

Figure 3: Global Sales for MRSA Therapeutics by Drug Class, 2014 and 2024

Figure 4: Global Sales for MRSA Therapeutics by Infection Site, 2014–2024

Figure 5: Global Sales for Branded MRSA Products by Company, 2014 and 2024

Figure 6: Company Portfolio Gap Analysis in MRSA, 2014–2024

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports